Rallybio posts Q3 net income of $16.0M on $20M REV102 sale; RLYB116 data expected Q4 2025

Rallybio Corp

2025-Q3 EPS reported -$0.07 revenue$636,000

Revenue $0.2M vs $0.3M YoY; R&D expenses fell to $4.1M (from $8.2M); G&A $3.0M (from $4.1M).
Net income $16.0M ($0.36/share) vs net loss $11.5M in Q3 2024; includes $20M from sale of REV102 interest.
Cash and securities $59.3M as of Sept 30; expected to fund operations through 2027.
Completed Cohort 1 dosing of RLYB116 confirmatory PK/PD study; data on track for Q4 2025.
RLYB332 development plans being evaluated; preclinical data show superior PD vs comparator molecules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.